These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30010165)

  • 1. High affinity single-chain variable fragments are specific and versatile targeting motifs for extracellular vesicles.
    Longatti A; Schindler C; Collinson A; Jenkinson L; Matthews C; Fitzpatrick L; Blundy M; Minter R; Vaughan T; Shaw M; Tigue N
    Nanoscale; 2018 Aug; 10(29):14230-14244. PubMed ID: 30010165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity.
    Wang L; Zhou X; Zou W; Wu Y; Zhao J; Chen X; Zhou GG
    J Nanobiotechnology; 2020 Oct; 18(1):153. PubMed ID: 33109196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered Exosomes for Targeted Transfer of siRNA to HER2 Positive Breast Cancer Cells.
    Limoni SK; Moghadam MF; Moazzeni SM; Gomari H; Salimi F
    Appl Biochem Biotechnol; 2019 Jan; 187(1):352-364. PubMed ID: 29951961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid On-Demand Extracellular Vesicle Augmentation with Versatile Oligonucleotide Tethers.
    Yerneni SS; Lathwal S; Shrestha P; Shirwan H; Matyjaszewski K; Weiss L; Yolcu ES; Campbell PG; Das SR
    ACS Nano; 2019 Sep; 13(9):10555-10565. PubMed ID: 31436946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly efficient production of anti-HER2 scFv antibody variant for targeting breast cancer cells.
    Sommaruga S; Lombardi A; Salvadè A; Mazzucchelli S; Corsi F; Galeffi P; Tortora P; Prosperi D
    Appl Microbiol Biotechnol; 2011 Aug; 91(3):613-21. PubMed ID: 21538107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved biological activity of a single chain antibody fragment against human epidermal growth factor receptor 2 (HER2) expressed in the periplasm of Escherichia coli.
    Akbari V; Sadeghi HM; Jafarian-Dehkordi A; Abedi D; Chou CP
    Protein Expr Purif; 2015 Dec; 116():66-74. PubMed ID: 26166178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilization of exosome-targeting peptides via engineered glycosylation.
    Hung ME; Leonard JN
    J Biol Chem; 2015 Mar; 290(13):8166-72. PubMed ID: 25657008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes.
    Alric C; Hervé-Aubert K; Aubrey N; Melouk S; Lajoie L; Même W; Même S; Courbebaisse Y; Ignatova AA; Feofanov AV; Chourpa I; Allard-Vannier E
    J Nanobiotechnology; 2018 Feb; 16(1):18. PubMed ID: 29466990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapeutic delivery using engineered exosomes and its applications in cardiovascular diseases.
    Xitong D; Xiaorong Z
    Gene; 2016 Jan; 575(2 Pt 2):377-384. PubMed ID: 26341056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Display of single-chain variable fragments on bacteriophage MS2 virus-like particles.
    Lino CA; Caldeira JC; Peabody DS
    J Nanobiotechnology; 2017 Feb; 15(1):13. PubMed ID: 28193211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation of scFv antibody fragments against HER2 and CEA tumor antigens from combinatorial antibody libraries derived from cancer patients.
    Ayat H; Burrone OR; Sadghizadeh M; Jahanzad E; Rastgou N; Moghadasi S; Arbabi M
    Biologicals; 2013 Nov; 41(6):345-54. PubMed ID: 23845693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells.
    Motallebnezhad M; Younesi V; Aghebati-Maleki L; Nickho H; Safarzadeh E; Ahmadi M; Movassaghpour AA; Hosseini A; Yousefi M
    Tumour Biol; 2016 Nov; 37(11):14841-14850. PubMed ID: 27639384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
    Adams GP; Schier R; Marshall K; Wolf EJ; McCall AM; Marks JD; Weiner LM
    Cancer Res; 1998 Feb; 58(3):485-90. PubMed ID: 9458094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cloaked Exosomes: Biocompatible, Durable, and Degradable Encapsulation.
    Kumar S; Michael IJ; Park J; Granick S; Cho YK
    Small; 2018 Aug; 14(34):e1802052. PubMed ID: 30024108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomes: Therapy delivery tools and biomarkers of diseases.
    Barile L; Vassalli G
    Pharmacol Ther; 2017 Jun; 174():63-78. PubMed ID: 28202367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
    Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
    Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and characterization of recombinant humanized anti-HER2 single-chain antibody in Pichia pastoris for targeted cancer therapy.
    Cao X; Yu H; Chen C; Wei J; Wang P
    Biotechnol Lett; 2015 Jul; 37(7):1347-54. PubMed ID: 25735855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of exosome surface display technology in living human cells.
    Stickney Z; Losacco J; McDevitt S; Zhang Z; Lu B
    Biochem Biophys Res Commun; 2016 Mar; 472(1):53-9. PubMed ID: 26902116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.
    Zhang K; Geddie ML; Kohli N; Kornaga T; Kirpotin DB; Jiao Y; Rennard R; Drummond DC; Nielsen UB; Xu L; Lugovskoy AA
    MAbs; 2015; 7(1):42-52. PubMed ID: 25484041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
    Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
    Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.